UTI Drugs Market Size to Hit USD 8.65 Billion by 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on UTI Drugs Market

5.1. COVID-19 Landscape: UTI Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global UTI Drugs Market, By Drug Class

8.1. UTI Drugs Market Revenue and Volume Forecast, by Drug Class

8.1.1. Fluoroquinolones

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Cephalosporins

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Nitrofurantoin

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Trimethoprim-sulfamethoxazole

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Fosfomycin

8.1.5.1. Market Revenue and Volume Forecast

8.1.6. Penicillins

8.1.6.1. Market Revenue and Volume Forecast

8.1.7. Carbapenems

8.1.7.1. Market Revenue and Volume Forecast

8.1.8. Aminoglycosides

8.1.8.1. Market Revenue and Volume Forecast

Chapter 9. Global UTI Drugs Market, By Route of Administration

9.1. UTI Drugs Market Revenue and Volume Forecast, by Route of Administration

9.1.1. Oral

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Intravenous

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Intramuscular

9.1.3.1. Market Revenue and Volume Forecast

Chapter 10. Global UTI Drugs Market, By Indication Type

10.1. UTI Drugs Market Revenue and Volume Forecast, by Indication Type

10.1.1. Uncomplicated UTI

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Complicated UTI

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Pyelonephritis

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Recurrent UTI prophylaxis

10.1.4.1. Market Revenue and Volume Forecast

Chapter 11. Global UTI Drugs Market, By Distribution Channel

11.1. UTI Drugs Market Revenue and Volume Forecast, by Distribution Channel

11.1.1. Hospital pharmacy

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Retail pharmacy

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Online pharmacy

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Clinic dispensing

11.1.4.1. Market Revenue and Volume Forecast

Chapter 12. Global UTI Drugs Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Drug Class

12.1.2. Market Revenue and Volume Forecast, by Route of Administration

12.1.3. Market Revenue and Volume Forecast, by Indication Type

12.1.4. Market Revenue and Volume Forecast, by Distribution Channel

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Drug Class

12.1.5.2. Market Revenue and Volume Forecast, by Route of Administration

12.1.5.3. Market Revenue and Volume Forecast, by Indication Type

12.1.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Drug Class

12.1.6.2. Market Revenue and Volume Forecast, by Route of Administration

12.1.6.3. Market Revenue and Volume Forecast, by Indication Type

12.1.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Drug Class

12.2.2. Market Revenue and Volume Forecast, by Route of Administration

12.2.3. Market Revenue and Volume Forecast, by Indication Type

12.2.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Drug Class

12.2.5.2. Market Revenue and Volume Forecast, by Route of Administration

12.2.5.3. Market Revenue and Volume Forecast, by Indication Type

12.2.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Drug Class

12.2.6.2. Market Revenue and Volume Forecast, by Route of Administration

12.2.6.3. Market Revenue and Volume Forecast, by Indication Type

12.2.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Drug Class

12.2.7.2. Market Revenue and Volume Forecast, by Route of Administration

12.2.7.3. Market Revenue and Volume Forecast, by Indication Type

12.2.7.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Drug Class

12.2.8.2. Market Revenue and Volume Forecast, by Route of Administration

12.2.8.3. Market Revenue and Volume Forecast, by Indication Type

12.2.8.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Drug Class

12.3.2. Market Revenue and Volume Forecast, by Route of Administration

12.3.3. Market Revenue and Volume Forecast, by Indication Type

12.3.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Drug Class

12.3.5.2. Market Revenue and Volume Forecast, by Route of Administration

12.3.5.3. Market Revenue and Volume Forecast, by Indication Type

12.3.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Drug Class

12.3.6.2. Market Revenue and Volume Forecast, by Route of Administration

12.3.6.3. Market Revenue and Volume Forecast, by Indication Type

12.3.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Drug Class

12.3.7.2. Market Revenue and Volume Forecast, by Route of Administration

12.3.7.3. Market Revenue and Volume Forecast, by Indication Type

12.3.7.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Drug Class

12.3.8.2. Market Revenue and Volume Forecast, by Route of Administration

12.3.8.3. Market Revenue and Volume Forecast, by Indication Type

12.3.8.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Drug Class

12.4.2. Market Revenue and Volume Forecast, by Route of Administration

12.4.3. Market Revenue and Volume Forecast, by Indication Type

12.4.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Drug Class

12.4.5.2. Market Revenue and Volume Forecast, by Route of Administration

12.4.5.3. Market Revenue and Volume Forecast, by Indication Type

12.4.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Drug Class

12.4.6.2. Market Revenue and Volume Forecast, by Route of Administration

12.4.6.3. Market Revenue and Volume Forecast, by Indication Type

12.4.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Drug Class

12.4.7.2. Market Revenue and Volume Forecast, by Route of Administration

12.4.7.3. Market Revenue and Volume Forecast, by Indication Type

12.4.7.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Drug Class

12.4.8.2. Market Revenue and Volume Forecast, by Route of Administration

12.4.8.3. Market Revenue and Volume Forecast, by Indication Type

12.4.8.4. Market Revenue and Volume Forecast, by Distribution Channel

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Drug Class

12.5.2. Market Revenue and Volume Forecast, by Route of Administration

12.5.3. Market Revenue and Volume Forecast, by Indication Type

12.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Drug Class

12.5.5.2. Market Revenue and Volume Forecast, by Route of Administration

12.5.5.3. Market Revenue and Volume Forecast, by Indication Type

12.5.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Drug Class

12.5.6.2. Market Revenue and Volume Forecast, by Route of Administration

12.5.6.3. Market Revenue and Volume Forecast, by Indication Type

12.5.6.4. Market Revenue and Volume Forecast, by Distribution Channel

Chapter 13. Company Profiles

13.1. Pfizer Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial PerDrug Classance

13.1.4. Recent Initiatives

13.2. AbbVie Inc.

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial PerDrug Classance

13.2.4. Recent Initiatives

13.3. Allergan Plc

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial PerDrug Classance

13.3.4. Recent Initiatives

13.4. Bayer AG

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial PerDrug Classance

13.4.4. Recent Initiatives

13.5. Novartis International AG.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial PerDrug Classance

13.5.4. Recent Initiatives

13.6. Sanofi S.A.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial PerDrug Classance

13.6.4. Recent Initiatives

13.7. Teva Pharmaceutical Industries Ltd

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial PerDrug Classance

13.7.4. Recent Initiatives

13.8. Sun Pharmaceutical Industries Ltd

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial PerDrug Classance

13.8.4. Recent Initiatives

13.9. Dr. Reddy's Laboratories Ltd.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial PerDrug Classance

13.9.4. Recent Initiatives

13.10. Bristol-Myers Squibb Company

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial PerDrug Classance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

Answer : The UTI drugs market size is expected to increase from USD 5.06 billion in 2025 to USD 8.65 billion by 2035.

Answer : The UTI drugs market is expected to grow at a compound annual growth rate (CAGR) of around 5.50% from 2026 to 2035.

Answer : The major players in the UTI drugs market include Pfizer Inc., AbbVie Inc., Allergan Plc, Bayer AG, Novartis International AG., Sanofi S.A., Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca plc, Merck & Co. Inc, GlaxoSmithKline PLC, Eli Lilly and Company, Boehringer Ingelheim GmbH, Glenmark Pharmaceuticals Limited, Mylan N.V., Bio-Rad Laboratories Inc.and Cipla Ltd

Answer : The driving factors of the UTI drugs market are the by high UTI rates in women and older adults, antibiotic resistance, and better diagnostic methods, leading to a growing interest in targeted and combination therapies.

Answer : North America region will lead the global UTI drugs market during the forecast period 2026 to 2035.